

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

RENHUANG PHARMACEUTICALS INC  
Form NT 10-Q  
March 17, 2008

SEC File No: O-24512  
CUSIP No: 75971B 10 2

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):  Form 10-K  Form 20-F  Form 10-Q  Form 10-D  
 Form N-SAR  Form N-CSR

For Period Ended: January 31, 2008  
-----

Transition report on Form 10-K  
 Transition report on Form 20-F  
 Transition report on Form 11-K  
 Transition report on Form 10-Q  
 Transition report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Read Instruction (on back page) Before Preparing Form  
Please Print or Type. Nothing in this form shall be construed to imply that  
the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify  
the Item(s) to which the notification relates:  
-----

PART 1 -- REGISTRANT INFORMATION  
-----

Renhuang Pharmaceuticals, Inc.  
-----

Full Name of Registrant  
-----

Former name if Applicable  
-----

No. 218, Taiping, Taiping District  
-----

Address of Principal Executive Office (Street and Number)  
-----

Harbin, Heilongjiang Province, P.R. China 150050  
-----

City, State and Zip Code  
-----

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense  
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should  
be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this  
form could not be eliminated without unreasonable effort or

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

expense;

- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or a portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
- [X]

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Data and other information regarding certain material operations of the Company, as well as its financial statements required for the filing, are not currently available and could not be made available without unreasonable effort and expense.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Li Shaoming	+86 (451)	5762-0378
-----		
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

[X]Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[ ]Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

-----

Renhuang Pharmaceuticals, Inc.  
-----  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date March 13, 2008 By /s/ Li Shaoming

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

-----

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

.....

Intentional misstatements or omissions of fact constitute  
Federal Criminal Violations (See 18 U.S.C. 1001)

.....